ClinicalTrials.gg
WithdrawnNCT06384820Updated Jul 26, 2024

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

A Phase 2 interventional study of cemiplimab and fianlimab in Cutaneous Squamous Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is researching an investigational drug called REGN2810, also known as cemiplimab, and when combined with another investigational drug called REGN3767, also known as fianlimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on a type of skin cancer known as cutaneous squamous cell carcinoma (CSCC).

The aim of the study is to see if cemiplimab or cemiplimab in combination with fianlimab can eliminate or reduce the number of living cancer cells in tumor(s) if taken before surgery.

The study is looking at several other research questions, including:

  • Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make it possible to have a less extensive surgery or a different treatment plan after surgery
  • Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make the cancer less likely to come back after surgery
  • What side effects may happen from taking the cemiplimab or cemiplimab in combination with fianlimab
  • How much of the cemiplimab or cemiplimab in combination with fianlimab is in the blood at different times
  • Whether the body makes antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)
02

Conditions studied

  • Cutaneous Squamous Cell Carcinoma

Keywords

  • Neoadjuvant
  • Adjuvant
  • Surgery
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Stage III/IV (M0) CSCC, for which surgery would be recommended in routine clinical practice
  2. Tumor is required during screening period as described in the protocol
  3. Participant is willing to undergo delayed surgery
  4. At least 1 lesion that is measurable by (RECIST) v1.1
  5. (ECOG) performance status of 0 or 1
  6. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

  1. Stage I or II CSCC
  2. Anogenital, penile, vermilion lip CSCC
  3. CSCC bone invasion
  4. Solid within 5 years of the projected enrollment date, or hematologic malignancy as described in the protocol
  5. Prior radiation therapy for CSCC
  6. Myocardial infarction within 6 months of enrollment, or history of myocarditis.
  7. Prior treatment with anti-cancer systemic therapy within the last 3 years prior to projected enrollment date as described in the protocol

Note: Other protocol-defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    cemiplimab

    Drug: cemiplimab

  • Experimental
    fianlimab+cemiplimab

    Drug: cemiplimab · Drug: fianlimab

Interventions

  • Administered Intravenous (IV) infusion every three weeks (Q3W)

    Also known as: REGN2810, Libtayo

  • IV infusion Q3W

    Also known as: REGN3767

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate by blinded independent pathological review (BIPR)

    Time frame: Up to 100 days

Secondary outcomes

  1. pCR rate by local pathological review

    Time frame: Up to 100 days

  2. Major pathological response (MPR)

    Time frame: Up to 100 days

  3. Event-free survival (EFS)

    Time frame: Up to 3 years

  4. Disease free survival (DFS)

    Time frame: Up to 3 years

  5. Objective response rate (ORR) prior to surgery

    Time frame: Up to 100 days

  6. Overall survival (OS)

    Time frame: Up to 3 years

  7. Occurrence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 3 years

  8. Occurrence of immune-mediated adverse events (imAEs)

    Time frame: Up to 3 years

  9. Occurrence of treatment-related TEAEs

    Time frame: Up to 3 years

  10. Occurrence of adverse event of special interest (AESI)

    Time frame: Up to 3 years

  11. Occurrence of treatment-emergent serious adverse events (SAEs)

    Time frame: Up to 3 years

  12. Occurrence of laboratory abnormalities

    Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: Up to 3 years

  13. Occurrence of death due to TEAE

    Time frame: Up to 3 years

  14. Occurrence of interruption of study drug(s) due to TEAEs

    Time frame: Up to 3 years

  15. Occurrence of discontinuation of study drug(s) due to TEAEs

    Time frame: Up to 3 years

  16. Occurrence of cancellation of surgery due to TEAE

    Time frame: Up to 100 days

  17. Occurrence of delay to surgery due to TEAE

    Time frame: Up to 100 days

  18. Concentrations of cemiplimab in serum

    Time frame: Up to 3 years

  19. Concentrations of fianlimab in serum

    Time frame: Up to 3 years

  20. Concentrations of other experimental agents (as applicable) in serum

    Time frame: Up to 3 years

  21. Incidence of anti-drug antibodies (ADA) to cemiplimab

    Time frame: Up to 3 years

  22. Incidence of ADA to fianlimab

    Time frame: Up to 3 years

  23. Incidence of ADA to other experimental agents (as applicable)

    Time frame: Up to 3 years

  24. Titer of ADA to cemiplimab

    Time frame: Up to 3 years

  25. Titer of ADA to fianlimab

    Time frame: Up to 3 years

  26. Titer of ADA to other experimental agents (as applicable)

    Time frame: Up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Jun 2026, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartEst.
Nov 14, 2024
Primary completionEst.
Jun 8, 2026
CompletionEst.
May 6, 2030
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06384820
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Nov 14, 2024 (estimated)
Primary completion
Jun 8, 2026 (estimated)
Completion
May 6, 2030 (estimated)
Last update
Jul 26, 2024

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion